Voyager Therapeutics, Inc.
75 Hayden Avenue
Lexington, MA 02421
United States
857 259 5340
https://www.voyagertherapeutics.com
版塊: Healthcare
行業: Biotechnology
全職員工: 162
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Alfred W. Sandrock Jr., M.D., Ph.D. | President, CEO & Director | 1.01M | 無 | 1958 |
| Ms. Robin Swartz | COO, Principal Financial & Accounting Officer and Acting Chief Business Officer | 661.98k | 無 | 1971 |
| Ms. Jacquelyn Fahey Sandell Esq., J.D. | Chief Legal Officer | 538.16k | 無 | 1971 |
| Dr. Krystof Bankiewicz M.D., Ph.D. | Founder | 無 | 無 | 無 |
| Dr. Guangping Gao Ph.D. | Founder & Member of Scientific Advisory Board | 無 | 無 | 無 |
| Dr. Mark A. Kay M.D., Ph.D. | Founder | 無 | 無 | 1959 |
| Dr. Phillip D. Zamore Ph.D. | Founder & Member of Scientific Advisory Board | 無 | 無 | 無 |
| Mr. Todd Carter Ph.D. | Chief Scientific Officer | 無 | 無 | 1970 |
| Ms. Michelle Quinn Smith | Chief Human Resources Officer | 無 | 無 | 無 |
| Dr. Maria Lopez-Bresnahan M.B.A., M.D. | Senior Vice President of Translational Medicine & Clinical Development | 無 | 無 | 無 |
描述
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
公司管治
截至 2024年5月1日 止，Voyager Therapeutics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：3；董事會：7；股東權利：8；現金賠償：8。
